reimbursement The country manager of a JNJ affiliated company advocates deploying electronic healthcare techniques to transform the reach of local practitioners and speaks out about the sort of local adaptations that need to be considered when introducing new products to the Algerian market. What is your evaluation of the Algerian pharmaceutical…
respiratory disease The country manager of an Italian pharmaceutical firm talks about the evolution of Algerian health needs and what her firm is doing to counter different forms of respiratory disease prevalent in the country. After eighteen years at Chiesi, what have been your main successes to date? On a personal note,…
rare diseases The country manager of a leading German chemical and pharmaceutical company sheds light on her company’s activities in the rare diseases segment and speaks about the multiple benefits of promoting home care and greater patient autonomy. You are known for your medicines against diseases that are often neglected, such as…
biosimilars Christopher Ko was appointed as the Chief Executive Officer of Samsung Bioepis in 2012, then newly founded Korean pharmaceutical company with expertise in biosimilars. In this interview, he discusses the opportunities in Biosimilar markets as well as the potential impact the Samsung brand will bring to the pharmaceutical industry. As…
biosimilars Brothers Juan José and Andrés Aguirre Salazar of Grupo Bruluart talk about the company’s most important milestones and how they are institutionalizing the family business to prepare the firm for new market opportunities. Could you walk us through the most important milestones of the company and provide our readers with…
generics Carlos Leigh, executive president of Peru’s Asociación de Laboratorios Farmacéuticos Latinoamericanos (ALAFAL), discusses the advantages that LATAM companies have over big pharma players looking to enter the Peruvian market, and offers his predictions for the future of the sector for growth. Can you introduce yourself to our readers? I actively worked in…
investemnt The stability of Peru’s economy in recent years has provided amply opportunity for multinational pharmaceutical companies to invest in the country. Augusto Rey de la Cuba, executive director of ALAFARPE (Asociación Nacional de Laboratorios Faramcéuticos de Perú), discusses intellectual property issues and investing in research in the country. Can you…
clinical trials Auh June-Sun, chairman of Ahngook Pharm, describes the company’s increased focus on R&D and doing US FDA clinical trials. Can you describe your background and introduce yourself to our readers? 2014 was the 55th anniversary of Ahngook’s foundation. I have worked for Ahngook most of my career, although I did…
biotech The executive managing director of a leading American healthcare provider offering an innovative range of products on the local Algerian market treating asthma, diabetes, hepatitis and cholesterol speaks about the company’s experience and the country’s ambition to become a biotech leader For the pharmaceutical industry, the African continent – especially…
pharmaceuticals With a wealth of experience in different countries around the world, Christophe Piganiol came to Korea as general manager of Zuellig Pharma in 2010. Today he discusses the importance of transparency in a volatile market and the introduction of new business models to satisfy customer demand. What were your impressions…
clinical research Clinical research and access are the name of the game. The Executive Director of the association bringing together the most important research-based pharmaceutical companies discusses how the association has stepped up to partner up with the government and stakeholders to fight for the same objective and create a better health…
biotechnology The genomic revolution represents a before and after in the field of medicine. Sistemas Genómicos has understood this back in 1998 and today is the largest private organization offering DNA and RNA sequencing in Spain. The director for Latin America and country manager for Mexico discuss the unmet needs they…
See our Cookie Privacy Policy Here